Carregant...
High CCR4 expression in the tumor microenvironment is a poor prognostic indicator in lung adenocarcinoma
BACKGROUND: Clinical trials of anti-CCR4 antibody for solid cancers with or without other immune-modulating agents including immune checkpoint blockade therapy are currently underway. However, little is known about the roles of CCR4(+) lymphocytes and their prognostic impact in lung cancer. We hypot...
Guardat en:
| Publicat a: | J Thorac Dis |
|---|---|
| Autors principals: | , , , , , , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
AME Publishing Company
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6129889/ https://ncbi.nlm.nih.gov/pubmed/30233846 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jtd.2018.07.45 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|